Genomic Health's Q4 Revenues Soar on Strong Adoption of Oncotype DX | GenomeWeb
NEW YORK (GenomeWeb News) – Genomic Health yesterday reported more than double-digit growth in its fourth-quarter revenues fueled by increasing adoption of its Oncotype DX breast cancer recurrence test.
 
Revenues for the quarter ended Dec. 31, 2007, grew by 124 percent to $19.3 million from $8.6 million in the fourth quarter of 2006.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.